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Objectives The study examined whether progression of coronary artery calcium (CAC) is a predictor of future coronary heart
disease (CHD) events.
Background CAC predicts CHD events and serial measurement of CAC has been proposed to evaluate atherosclerosis progression.
Methods We studied 6,778 persons (52.8% female) aged 45 to 84 years from the MESA (Multi-Ethnic Study of Ath-
erosclerosis) study. A total of 5,682 persons had baseline and follow-up CAC scans approximately 2.5  0.8
years apart; multiple imputation was used to account for the remainder (n  1,096) missing follow-up
scans. Median follow-up duration from the baseline was 7.6 (max  9.0) years. CAC change was assessed
by absolute change between baseline and follow-up CAC. Cox proportional hazards regression providing haz-
ard ratios (HRs) examined the relation of change in CAC with CHD events, adjusting for age, gender, ethnic-
ity, baseline calcium score, and other risk factors.
Results A total of 343 and 206 hard CHD events occurred. The annual change in CAC averaged 24.9  65.3 Agatston
units. Among persons without CAC at baseline (n  3,396), a 5-unit annual change in CAC was associated with
an adjusted HR (95% Confidence Interval) of 1.4 (1.0 to 1.9) for total and 1.5 (1.1 to 2.1) for hard CHD. Among
those with CAC 0 at baseline, HRs (per 100 unit annual change) were 1.2 (1.1 to 1.4) and 1.3 (1.1 to 1.5),
respectively. Among participants with baseline CAC, those with annual progression of 300 units had adjusted
HRs of 3.8 (1.5 to 9.6) for total and 6.3 (1.9 to 21.5) for hard CHD compared to those without progression.
Conclusions Progression of CAC is associated with an increased risk for future hard and total CHD events. (J Am Coll Car-
diol 2013;61:1231–9) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.12.035Coronary artery calcium (CAC) is strongly associated with
atherosclerotic burden and predicts coronary heart disease
(CHD) events and mortality (1–4). CAC scanning has been
proposed as a measure to track CHD progression and the
effects of risk factor modification on atherosclerosis (5,6).
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the relation of CAC progression
to CHD incidence in a large
multiethnic sample of U.S. adults in
a population-based prospective
study.
Methods
Study population and definitions.
The MESA (Multi-Ethnic Study of
Atherosclerosis) study is a prospective study of cardiovascu-
lar disease (11). A total of 6,814 participants ages 45 to 84
years free of clinical cardiovascular disease and identified as
White, Black, Hispanic, or Chinese, were recruited from 6
U.S. communities (Forsyth County, North Carolina;
Northern Manhattan and the Bronx, New York; Baltimore
City and Baltimore County, Maryland; St. Paul, Minne-
sota; Chicago, Illinois; Los Angeles County, California) in
2000 to 2002. Recruitment was conducted on the basis of
lists of residents, dwellings, telephone exchanges, lists of
Medicare beneficiaries, and referrals by participants. All
participants gave informed consent, and the study protocol
was approved by the Institutional Review Board at each site.
This report includes 6,778 participants with follow-up for
events, of which 5,682 subjects had both baseline (Exam 1)
and follow-up (Exam 2 or 3) CT scans and with no interim
CHD events. Multiple imputation (12,13) (described sub-
sequently) was used for the 1,096 participants who did not
have a follow-up CAC measure, including 141 individuals
who experienced a CHD event prior to their second scan.
Measurement of CAC. CAC was measured by electron-
beam (3 sites) or multidetector (3 sites) CT. Participants
were scanned twice consecutively (at each baseline and
follow-up) and scans were read by a trained physician-reader
at a centralized reading center (Los Angeles Biomedical
Research Institute, Torrance, California). The methodology
for acquisition and interpretation of the scans has been
published (14–16). Calcium volume scores and Agatston
scores were determined on the basis of averaging results
from each of the 2 scans done at the examination, and
adjusted using a standard calcium phantom. Detectable
calcium was defined as a CAC score 0. A repeat pair of
scans was performed on one-half of the cohort (randomly
selected) at a second MESA study clinical exam (September
2002 to January 2004) and on the other one-half at a third
exam (March 2004 to July 2005), averaging 2.5 years after
the baseline scans. Mean  SD absolute and % interscan
variability and correlation (r) were 19.8 59.6, 20.82%, and
0.99 between the paired scans at baseline and 23.6  61.7,
22.40%, and 0.99 between the paired scans at follow-up,
respectively. The distribution of CAC in the MESA study
at baseline by age, gender, and race has been published (17).
Examination data and covariates. Information on demo-
graphics, smoking, medical conditions, and family history
Abbreviations
and Acronyms
CAC  coronary artery
calcium
CHD  coronary heart
disease
CT  computed
tomography
HR  hazard ratiowas obtained by questionnaire. Height, weight, fasting totaland high-density lipoprotein cholesterol, triglycerides, and
glucose levels were determined. Resting blood pressure was
measured 3 times, with the average of the last 2 measure-
ments used in analysis. Cholesterol, blood pressure, and
diabetes medications were determined by questionnaire and from
medication containers. Diabetes was defined as a fasting glucose
7.0 mmol/l (126 mg/dl), or use of insulin or oral hypoglycemic
medications.
Follow-up. The cohort was followed for incident CHD
events for a median of 7.6 (max  9.0) years following the
performance of the baseline CT scan (4.8 years following
the second scan for the complete case analysis, see subse-
quent sections). At intervals of 9 to 12 months, a telephone
interviewer inquired about interim hospital admissions,
cardiovascular diagnoses, and deaths. An adjudication com-
mittee received copies of all death certificates and medical
records for hospitalizations and outpatient cardiovascular
diagnoses. Total CHD endpoints included myocardial in-
farction, probable angina if followed by revascularization,
resuscitated cardiac arrest, and CHD death. Hard CHD
included myocardial infarction and fatal CHD. Two phy-
sicians from the MESA study events committee indepen-
dently reviewed all medical records and death certificates for
endpoint classification and assignment of incidence dates.
The reviewers were blinded to CT results and used pre-
specified criteria.
Statistical analysis. Separate analyses were done for those
with baseline CAC  0 (n  3,396) and those with CAC
0 (n  3,382). Absolute progression rates were annualized.
nalyses were conducted on the basis of Agatston scores with
econdary analyses repeated using volume scores. For all
issing information, multiple imputation (12,13) using a
hained equation approach (18) was used to replace each
issing value with a set of 100 plausible substitutes that were
onsistent with the observed values. For persons without
ollow-up CAC scans (n  1,096), follow-up CAC at Exam
or 3 was predicted using regression equations on the basis of
he observed data, using baseline risk factors, baseline CAC
for those with CAC 0), CHD events, time to CHD event,
r last follow-up. Prior literature has described the rationale
nd necessity of including these variables in multiple imputa-
ion prediction equations (19–21) and imputation with re-
eated measures (13).
Follow-up CAC measures were imputed separately for
articipants with baseline CAC  0 and CAC 0 at the
time when they would have been given a second scan
(estimated or actual date of follow-up exam), and assumed
a linear rate of change in CAC. In those with intervening
initial CHD events, the degree of progression (and
follow-up time) was determined on the basis of the date of
occurrence of the event, imputing what the follow-up scan
score would have been at that time. A conditional (2-part)
imputation was done for subjects with CAC  0. The first
step predicted the likelihood of any CAC progression using
logistic regression; the second part was conditioned on the
first and only those who were predicted to have had
st
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0. The conditional imputation allowed adequate modeling
of the relatively large proportion of participants with base-
line CAC  0 who experienced no progression. Parameter
estimates were averaged across the multiple datasets and
using Rubin’s rules (12) to combine the standard errors
when applicable.
CHD event rates were annualized and reported per 1,000
person-years, overall and according to absolute change
categories (no change, and 0 in those without CAC at
baseline and no/negative change, 0.01 to 99, 100 to 199,
200 to 299, and 300 in those with CAC at baseline). In
those with CAC at baseline (excluding those with scores
10 due to spuriously high relative changes from small
score increases), CHD event rates are also reported in terms
of annualized percentage change in CAC (5%, 5% to
15%, 15% to 30%, and 30%).
For those with baseline CAC  0, Cox proportional
hazards regression modeled the change in CAC both as a
dichotomous variable comparing those with any progression
to those who remained at zero, and as a continuously per
5-U change in progression. For those with CAC 0, we
chose intervals of 100 units of change per year compared to
those who had 0 change, and as a continuous variable in
units of 100 change per year. Results are also presented in
terms of the annualized percentage of change categories as
described previously. In the imputed analyses, follow-up
time was calculated from the time of the baseline scan since
progression was imputed in cases of intervening CHD
events or where second scans were unavailable; for the
complete case analysis, it was calculated from the time of the
second scan. Models both unadjusted and adjusted for age,
gender, ethnicity, and baseline total and high-density lipo-
protein cholesterol, lipid-lowering medication, systolic and
diastolic blood pressure, hypertension medication, smoking,
diabetes, family history, and baseline CAC score were run.
Sensitivity analyses were also done adjusting for baseline
and follow-up interscan variability as well as including those
with percutaneous interventions or bypass surgery, which
were not included in the MESA total CHD endpoint. All
analyses were conducted with Stata statistical software
(version 12.1, College Station, Texas).
Results
Overall 3,382 (49.9%) of participants had CAC at baseline;
12% of our sample were Black, 28% were Chinese, 38%
were White, and 22% were Hispanic. Participants with
CAC at baseline were more likely to be older and male, and
have diabetes, have previously smoked, have a family history
of MI or stroke, and be on lipid-lowering or antihyperten-
sive medication. Of those with baseline CAC  0, 84.2%
were still 0 at the follow-up scan and 15.8% showed
progression (median progression 2.2 U/year). For those
with CAC 0, 15.2% did not progress, whereas 84.8%
howed progression (median progression 28.9 U/year)(Table 1). Among those with baseline CAC scores of 0,
0.001 to 99, 100 to 199, 200 to 299, and 300, median
annual progression was 2.2, 8.3, 28.4, 44.0, and 103.3
units/year, respectively, for the imputed analysis and 0, 7.9,
27.7, 43.2, and 95.5 U/year, respectively, for the nonim-
puted analysis. There were 343 total incident CHD events,
of which 206 were hard CHD events (of which 148 and 88
occurred before a second scan so were thus included in
imputed analyses).
Figure 1 shows the Kaplan-Meier failure estimates with
incident CHD being significantly greater comparing any to
no CAC change among those with baseline CAC  0 (p 
0.001 for the log-rank test). Figure 2 shows successively
greater cumulative proportions of incident CHD events
according to annual CAC change groupings among those
with baseline CAC0 (p 0.001 comparing CAC change
groups). Kaplan-Meier estimates were also determined for
the nonimputed samples (see Online Appendix).
Among those with CAC  0 at baseline, compared to
persons with no increase in CAC, any increases were
associated with 1.4- to 1.5-fold greater risks for CHD
events in adjusted analyses (Table 2). There was a 50%
greater risk for both total and hard CHD events per annual
increase of 5 U. The imputed models tended to have more
statistical power, although results were similar regardless of
which analytic strategy was used.
In Table 3, future CHD risk by progression of CAC in
hose with CAC 0 at baseline is compared to those with
o progression of CAC. Annual CAC increases of 100 U
onferred significant 2- to 3-fold greater risks for total and
ard CHD events in adjusted analyses, with annual total
HD event rates of 3% to 6%/year. Moreover, in secondary
nalyses (not shown) comparing the impact of using volume
cores versus Agatston scores, virtually identical results were
btained, with the adjusted risk (hazard ratio [95% confi-
ence interval]) of total CHD per SD unit absolute change
n CAC per year of 1.2 (1.1 to 1.3) for both Agatston score
nd for volume score. Baseline CAC was expectedly the
reatest contributor to risk (t  4.76, p  0.001), followed
y gender (t  3.78, p  0.001), systolic blood pressure
(t  3.55, p  0.001), and total cholesterol (t  3.28, p 
0.001); annualized calcium change was the next most
important predictor (t  2.92, p  0.001) of total CHD
events.
Table 4 shows the risk of total CHD events according to
percentage change categories in CAC and by annualized
percentage change as a continuous variable. Those with 15%
to 29% annual increases in CAC had an increased risk
(hazard ratio [HR]: 1.6) for total CHD events relative to
those with progression 5% annually.
In separate analyses (not shown), we examined the
threshold for which annualized absolute and relative (per-
cent change) progression were best associated with total
CHD event risk (comparing those at or above vs. below
different cutpoints using Cox proportional hazards regres-
sion in fully adjusted analyses); cutpoints at or above 25
L-C h
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25 U), or 15% annual increases (HR: 1.4, p 0.05) in CAC
were identified.
We also conducted a sensitivity analysis and compared
results from the total (imputed) and not imputed (complete
case) samples. In adjusted analyses, among those with CAC 0
at baseline, HRs per 5 U increase in CAC were identical (1.4,
p  0.05) for the total and not imputed samples (Table 5).
Among those with CAC 0 at baseline, a 100 unit annual
progression of CAC associated with HRs (95% Confidence
interval) of 1.2 (1.1 to 1.4) and 1.3 (1.2 to 1.5), respectively
(Table 6).
The MESA total CHD endpoint does not include
incident percutaneous interventions or bypass surgery be-
cause of concern that referral bias arising from the calcium
score could influence these events; including 29 such events
in our nonimputed analyses for total CHD showed adjusted
HRs for those with annual CAC increases of 100 to 199,
200 to 299, and 300 versus no or negative change that
were greater than when these events were not included (3.8
vs. 3.1, 4.7 vs. 3.2, and 5.8 vs. 3.8, respectively, all p 
0.001).
Finally, we examined the impact of adjusting for baseline
Descriptive Statistics: MESATable 1 Descriptive Statistics: MESA
Overall
Men
Women
Caucasian
Black
Chinese
Hispanic
Taking lipid-lowering medication
Taking antihypertensive medication
Smoker
Never
Former
Current
Diabetes
Family history of MI or stroke
Age, yrs
Total cholesterol, mmol/l (mg/dl)
HDL-C, mmol/l (mg/dl)
SBP, mm Hg
DBP, mm Hg
CAC at baseline
Median follow-up duration, yrs
Years between exams
Incidence of CAC in those with CAC 0
Median (25–75%tiles) CAC change/yr in those with
incident CAC
Progression of CAC in those with CAC 0
Median CAC change/yr in those with progression of CAC
Values are n (%), %, mean  SD, and median (25%–75%). Subjects in
CAC coronary artery calcium; DBP diastolic blood pressure; HD
systolic blood pressure.and follow-up interscan variability on total CHD by addingthese terms to the Cox proportional hazards regression and
found no relation with event risk (for baseline: HR: 0.8, 0.6
to 1.2; follow-up interscan variability: HR: 0.8, 0.5 to 1.3).
Results were largely unaffected with adjusted HRs for those
with score increases of 100 to 199, 200 to 299, and 300
versus no or negative change of 1.8 (1.0 to 3.2), 2.0 (1.0 to
4.0), and 2.4 (1.1 to 5.4), respectively, and 1.2 (1.1 to 1.4)
per 100 U annual change (compare to Table 3 not adjusted
for interscan variability).
Discussion
Serial evaluation of CAC has been proposed for measuring
progression of atherosclerosis, and thus to predict CHD in
asymptomatic individuals. We observed graded relation-
ships of CAC progression with CHD event risk, strongly
suggesting that the functions are linear, with greater pro-
gression associated with greater risk. We demonstrated that
progression of CAC is associated with total and hard CHD
risk; these relationships remained significant after adjusting
for risk factors and baseline calcium. We demonstrated that
those with annual progression of300 U were 3 times more
likely to suffer CHD events in adjusted analyses. Compared
Baseline CAC  0 Baseline CAC >0
3,396 3,382
1,243 (36.6%) 1,953 (42.2%)
2,153 (63.4%) 1,429 (57.8%)
1,125 (33.1%) 1,489 (44.0%)
398 (11.7%) 402 (11.9%)
1,061 (31.2%) 819 (24.2%)
812 (23.9%) 672 (19.9%)
10.6% 21.8%
28.8% 45.8%
56.0% 44.6%
30.8% 42.5%
13.2% 12.9%
9.3% 15.9%
37.1% 48.3%
58.0 9.1 66.4 9.5
5.0 (193.7) 0.9 (35.0) 5.1 (194.6) 0.9 (36.4)
1.4 (52.5) 0.4 (15.0) 1.3 (49.5) 0.4 (14.5)
122.4 20.5 130.8 21.7
71.2 10.3 72.6 10.2
0 290.8 545.9
7.6 (max 9.0) 7.6 (max 8.9)
2.5 0.8 2.4 0.9
535 (15.8%)
2.2 (0.7–5.9)
2,869 (84.8%)
28.9 (60.9–529.1)
oth imputed and nonimputed cases.
igh-density lipoprotein cholesterol; MImyocardial infarction; SBPclude bwith those without progression of CAC, any progression of
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March 26, 2013:1231–9 Progression of Coronary Calcium and CHD EventsCAC in those with CAC 0 at baseline and progression of at
east 100 units in those with CAC 0 at baseline were
ssociated with increased CHD risk, with event rates of 3% to
%/year.
Our results are consistent with earlier smaller studies
howing that persons who experienced CHD events had
lso greater progression of CAC (7,8), as well as a recent
rospective study demonstrating a strong relation with total
ortality (9). The 3.3-fold increased mortality risk seen
ith CAC progression is similar to our 2- to 4-fold adjusted
Rs for CHD events. In a retrospective follow-up study of
17 persons, CAC progression was the strongest predictor
f myocardial infarction (26). Another study showed a
7-fold relative risk for acute myocardial infarction for
atients exhibiting 15% CAC progression when com-
ared to that of patients without CAC progression (7).
Of great interest has been whether risk-reducing thera-
ies such as statins may retard progression of atherosclerosis
ssessed by serial CAC scanning. In our study, mean
rogression rates were 46.2 for those not on statins com-
ared to 60.0 for statin users (p  0.001) and among those
ho suffered a CHD event, those on statins actually had
ore progression than those who were not on statins (119.3
/year vs. 55.7 U/year, respectively, among those with
AC0); this is not surprising from an observational study
uch as MESA where people receiving statins are generally
f higher risk than those not receiving statins. This impor-
ant observation argues against the concept that increased
AC on statins is benign or reflects only conversion of
oncalcified to calcified plaque rather than progression of
he underlying atherosclerotic process, although both pro-
esses may be present. Two important clinical trials did not
how differences in CAC progression between those treated
Figure 1 Kaplan-Meier Plot of Cumulative Incidence of
Total CHD Among Persons With CAC  0 at Baseline
Numbers in parenthesis indicate proportion of subjects in each group.
Imputed and nonimputed subjects are included. For log-rank test comparing
any versus no change in coronary artery calcium (CAC), p  0.001. CHD 
coronary heart disease.ersus not treated with statins (5,6).Important to understanding factors related to the pro-
ression of CAC is the baseline calcium score, a strong
redictor of CAC progression (27,28). While baseline CAC
an be considered a confounder, it can also be considered
art of the causal pathway between CHD risk factors and
AC progression. Persons with higher baseline CAC have
higher risk factor burden and, perhaps, more uncalcified
therosclerotic plaques destined for calcification and, thus,
ay exhibit greater future CAC progression. Thus, includ-
ng baseline CAC in the model could account for effects
hat variables of interest may have had before the initial scan
22). We show that CAC progression predicts CHD events
ven after adjustment for baseline risk factors and baseline
alcium score. Other reports also document the low pro-
ression and event rate in those with CAC  0 at baseline
6), which indicates a low risk of future CHD events for at
east 5 years (29).
We observed greater relative (%) increases in CAC (15%
r greater) to be associated with only modest increases in
HD risk that were less consistent than that seen with
bsolute increases. One explanation is that persons with
ower baseline scores but greater relative increases (e.g.,
ncreases from 15 to 30) are likely to be associated with less
isk than smaller relative, but greater absolute increases in
omeone with greater CAC burden (e.g., an increase from
00 to 500) who is at higher risk from the outset. These
xamples indicate why our findings regarding absolute CAC
ncreases are likely to be more applicable to most individual
atients, except in those with very high CAC scores (e.g., a
5% increase in CAC score in someone with a baseline score
f 1,000 is likely to be more important than an increase in
core of 100 U).
In our study, those with missing follow-up CAC scores
ad this information imputed on the basis of predicted
Figure 2 Kaplan-Meier Plot of Cumulative Incidence of
Total CHD Among Persons with CAC >0 at Baseline
Numbers in parenthesis indicate proportion of subjects in each group. Imputed
and nonimputed subjects are included. For log-rank test across CAC change
groups, p  0.001. Abbreviations as in Figure 1.
of the b
m
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Progression of Coronary Calcium and CHD Events March 26, 2013:1231–9CAC values from baseline CAC and risk factor relation-
ships. We present both nonimputed (only cases with follow-
up) and imputed cases in this study. Multiple imputation is
optimal for treating subjects likely to have been missing at
random, whereas complete case analysis requires the strin-
Hazard Ratio Examining the Likelihood of Total CHCAC Among Those W th CAC  0 at Baseline (MultTable 2 Haz rd Ratio Examin ng the LikelihooCAC Among Those With CAC  0 at B
Event rate per 1,000 person-years, annualized rate (%)
[events/subjects]
Absolute  in CAC/yr
No change
Any progression
Total
Hazard ratio (95% confidence interval)
Unadjusted absolute  in CAC/yr
No change
Any progression
Adjusted absolute  in CAC/yr*
No change
Any progression
Unadjusted absolute  in CAC/yr (per 5 U)
Adjusted absolute  in CAC/yr* (per 5 U)
Value are n(%) [events/subjects] or hazard ratios ( 95% Confidence int
lipid lowering medication, SBP and DBP, antihypertensive medication,
and nonimputed subjects; follow-up time is calculated from the time
CHD  coronary heart disease; other abbreviations as in Table 1.
Hazard Ratio Examining the Likelihood of Total CHD and Hard CHD byCAC Among Those With CAC > 0 at Baseline (Multi-Ethnic Study oTable 3 Hazard Ra io Examining the Likelihood of Total CHD andCAC Among Those With CAC > 0 at Baseline (Multi-E
Event rate per 1,000 person-years, annualized rate (%)
[events/subjects]
Absolute  in CAC/yr
No or negative change
0.001–100
100–200
200–300
300
Total
Hazard ratio (95% confidence interval)
Unadjusted absolute  in CAC/yr
No or negative change
0.001–100
100–200
200–300
300
Adjusted absolute  in CAC/yr*
No or negative change
0.001–100
100–200
200–300
300
Unadjusted absolute  in CAC/yr (per 100 U) [Mod
Adjusted absolute  in CAC/yr* (per 100 U) [Mod
Values are n (%) [events/subjects] or hazard ratio (95% Confidence interval). Adjusted for baseline
edication, smoking, diabetes, family history, and baseline CAC; change () analysis includes im2-tailed). ‡p  0.01 (2-tailed). §p  0.001 (2-tailed).
Abbreviations as in Tables 1 and 2.gent and unlikely assumption that the values are missing
completely at random (13,23,24). Our follow-up CAC
scores were clearly not missing completely at random
because the probability of missing a second scan was related
to other factors such as a greater likelihood of experiencing
d Hard CHD by Progression ofic Stu y of Atherosclero s MESA)otal CHD and Ha d CHD by Progression of
e (Multi-Ethnic Study of Atherosclerosis MESA)
Total CHD Hard CHD
1.6 (0.16) [34/2,861] 1.1 (0.11) [24/2,861]
2.6 (0.26) [10/535] 1.8 (0.18) [7/535]
1.8 (0.18) [44/3,396] 1.3 (0.13) [31/3,396]
[44/3,396] [31/3,396]
Reference Reference
1.5 (0.7–3.5) 1.5 (0.6–3.9)
[44/3,396] [31/3,396]
Reference Reference
1.0 (0.4–2.3) 1.1 (0.4–2.8)
4/3,396] 1.3† (1.1–1.8) [31/3,396] 1.4† (1.1–1.9)
4/3,396] 1.4† (1.0–1.9) [31/3,396] 1.5† (1.1–2.1)
Adjusted for baseline age, gender, ethnicity, total cholesterol, HDL-C,
g, diabetes, and family history; change () analysis includes imputed
aseline scan. †p  0.05 (2-tailed).
ression ofrosclerosis)CHD by Progression of
Study of Atherosclerosis)
Total CHD Hard CHD
(0.97) [33/513] 5.8 (0.58) [21/513]
.98) [157/2,309] 5.8 (0.58) [94/2,309]
(2.84) [62/372] 15.0 (1.50) [35/372]
(3.96) [25/113] 19.4 (1.94) [13/113]
(5.63) [22/75] 28.3 (2.83) [12/75]
1.31) [299/3,382] 7.5 (0.75) [175/3,382]
del: 299/3,382] [Model: 175/3,382]
Reference Reference
1.0 (0.6–1.7) 1.0 (0.5–1.9)
.0§ (1.7–5.4) 2.6† (1.2–5.8)
.3§ (2.4–8.4) 3.3‡ (1.9–8.6)
.9§ (3.0–11.6) 5.0§ (2.2–11.6)
del: 299/3,382] [Model: 175/3,382]
Reference Reference
1.0 (0.6–1.7) 1.0 (0.5–1.9)
.1† (1.1–3.8) 1.9 (0.8–4.5)
.4† (1.1–5.1) 2.1 (0.7–6.3)
.8† (1.2–5.4) 3.0† (1.0–8.9)
/3,382] 1.5§ (1.4–1.7) [Model: 175/3,382] 1.5§ (1.3–1.6)
9/3382] 1.2§ (1.1–1.4) [Model: 175/3,382] 1.3† (1.1–1.5)
nder, ethnicity, total cholesterol, HDL-C, lipid lowering medication, SBP and DBP, antihypertensive
and nonimputed subjects; follow-up is calculated from the time of the baseline scan. †p  0.05D ani-Ethd of T
aselin
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March 26, 2013:1231–9 Progression of Coronary Calcium and CHD Eventsan event (2.2 vs. 0.8 per 1,000 person-years) as well as
greater mean annual progression (73.1 vs. 44.9 U) compared
to observed cases in the CAC 0 group; thus, exclusion of
such individuals would have potentially biased the results
toward the null. It is worth noting that the results from the
imputed data showed no unexpected or major differences
when compared to the estimates from data that were not
imputed. While a complete case approach requires exclud-
Hazard Ratio Examining the Likelihood of TotalProg ession of CAC According to Percentage An(Multi-Ethn c Study of Atherosclerosis MESA)
Table 4
Haz rd Rati Examining the Lik lih
Progression of CAC According to P
(Multi-Ethnic Study of Atherosclero
Event rate per 1,000 person-years’ annualized rate (%)
[events/subjects]
Percentage  in CAC/yr
5%
5–14%
15–29%
30%
Total
Hazard ratio (95% confidence interval)
Unadjusted percentage  in CAC/yr
5%
5–14%
15–29%
30%
Adjusted percentage  in CAC/yr*
5%
5–14%
15–29%
30%
Values are n (%) [events/subjects] or hazard ratios (95% Confiden
percentage changes that can result from small absolute changes. 
lowering medication, SBP and DBP, antihypertensive medication, sm
includes imputed and nonimputed subjects; follow-up is calculated fro
Abbreviations as in Tables 1 and 2.
Hazard Ratio Examining the Likelihood of Total CHD by ProgressionWith CAC  0 at Baseline (Multi-Ethnic Study of Atheroscle o is),Table 5 Haz rd Rat o Examin ng the Likelih od of Total CHD byWith CAC  0 at Baseline (Multi-Ethnic Study of Athe
Event rate per 1,000 person-years’ annualized rate (%)
[events/subjects]
Absolute  in CAC/yr
No change
Any progression
Total
Hazard ratio (95% confidence interval)
Unadjusted absolute  in CAC/yr
No change
Any progression
Adjusted absolute  in CAC/yr*
No change
Any progression
Unadjusted absolute  in CAC/yr (per 5 units) [Mo
Adjusted absolute  in CAC/yr* (per 5 units) [Mo
Adjusted for baseline age, gender, ethnicity, total cholesterol, HDL, lipid lowering medication, SBP
survival time is calculated as the time between hard CHD and exam 2 or exam 3 depending on whether
Abbreviations as in Tables 1 and 2.ing intervening CHD events before a follow-up CAC scan,
the imputed models included these events, a major advantage.
Multiple imputation by using all available data provides for
more accurate estimates of effect sizes, despite little impact on
our findings.
Strengths of MESA include standardized risk factor
assessment, protocols for CAC scanning and interpretation,
and event ascertainment (11,14). Our data involved progres-
and Hard CHD byChange From Baselinef Total CHD and Hard CHD by
tage Annual Change From Baseline
ESA)
Total CHD Hard CHD
11.2 (1.12) [43/580] 6.8 (0.68) [27/580]
15.2 (1.52) [61/585] 8.3 (0.83) [35/585]
17.8 (1.78) [84/708] 9.7 (0.97) [47/708]
14.4 (1.44) [95/1,001] 8.7 (0.87) [58/1,001]
14.8 (1.48) [283/2,874] 8.5 (0.85) [167/2,874]
[Model: 283/2,874] [Model: 167/2,874]
Reference Reference
1.4 (0.8–2.3) 1.2 (0.6–2.4)
1.6† (1.0–2.6) 1.4 (0.8–2.6)
1.3 (0.8–2.1) 1.3 (0.7–2.5)
[Model: 283/2,874] [Model: 167/2,874]
Reference Reference
1.1 (0.7–1.8) 1.0 (0.5–1.9)
1.6 (1.0–2.5) 1.4 (0.8–2.6)
1.5 (0.9–2.4) 1.4 (0.7–2.8)
rval). Persons with baseline CAC 10 excluded due to substantial
d for baseline age, gender, ethnicity, total cholesterol, HDL-C, lipid
diabetes, family history, and baseline CAC; change  (); analysis
time of the baseline scan. †p  0.05 (2-tailed).
AC Among Thoseand Without Imputed Valuesgression of CAC Among Those
erosis), With and Without Imputed Values
al CHD Imputed Total CHD Not imputed
(0.16) [34/2,861] 1.2 (0.12) [15/2,470]
(0.26) [10/535] 3.1 (0.31) [7/469]
(0.18) [44/3,396] 1.5 (0.15) [22/2,939]
odel: 44/3,396] [Model: 22/2,939]
Reference Reference
1.5 (0.7–3.5) 2.6† (1.1–6.5)
odel: 44/3,396] [Model: 22/2,939]
Reference Reference
1.0 (0.4–2.3) 2.1 (0.8–5.3)
/3,396] 1.3† (1.1–1.8) [Model: 22/2,939] 1.4‡ (1.2–1.8)
/3,396] 1.4† (1.0–1.9) [Model: 22/2,754] 1.4† (1.1–1.8)
HTN medication, smoking, diabetes, and family history; change (); for the nonimputed analyses,CHDnualood o
ercen
sis M
ce inte
Adjuste
oking,of CWithPro
roscl
Tot
1.6
2.6
1.8
[M
[M
del: 44
del: 44
, DBP,
the follow-up CAC score is from exam 2/3. †p  0.05 (2-tailed). ‡p  0.01 (2-tailed).
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linear relation of time with extent of CAC progression, so
findings may have differed if longer term progression had
been studied, if the relation of time to progression were
nonlinear, or if a greater follow-up for events had been
conducted. Also, while the variance between our 2 paired
scans at baseline and follow-up, greater with higher absolute
CAC scores, would be expected to also relate to progression
of CAC; however, incorporating interscan variability into
our model had a negligible effect and CAC progression still
remained significantly associated with CHD event risk. Our
analyses are also conducted on the basis of Agatston scores
as these are more clinically utilized; however, we also ran our
primary analyses using volume score and found indistin-
guishable results. Also, in MESA a high correlation
(0.99) is seen between Agatston and volume scores so it is
not surprising the results are robust regardless of which
score is used.
Current guidelines suggest a CAC scan is reasonable for
risk assessment in those of low-intermediate or intermediate
risk, or with diabetes (30). The current study adds evidence
from a large well-characterized prospective study that CAC
progression predicts CHD events, independent of tradi-
tional risk factors and baseline CAC scores (31). Our data
Hazard Ratio Examining the Likelihood of Total CHD by ProgressionWith CAC > 0 at Baseline (Multi-Ethnic Study of Atheroscle o is),Table 6 Haz rd Rat o Examin ng the Likelih od of Total CHD byWith CAC > 0 at Baseline (Multi-Ethnic Study of Athe
Event rate per 1,000 person-years’ annualized rate (%)
[events/subjects]
Absolute  in CAC/yr
No or negative change
0.001–100
100–200
200–300
300
Total
Hazard ratio (95% confidence interval)
Unadjusted absolute  in CAC/yr
No or negative change
0.001–100
100–200
200–300
300
Adjusted absolute  in CAC/yr*
No or negative change
0.001–100
100–200
200–300
300
Unadjusted absolute  in CAC/yr (per 100 units) [Mod
Adjusted absolute  in CAC/yr* (per 100 units) [Mod
Values are n (%) [events/subjects] or hazard ratios (95% Confidence interval). *Adjusted for baseline
medication, smoking, diabetes, family history, and baseline CAC; change (); the imputed sampl
baseline scan; for the nonimputed analyses, survival time is calculated as the time between hard
(2-tailed). ‡p  0.01 (2-tailed). §p  0.001 (2-tailed).
Abbreviations as in Tables 1 and 2.showing increases in CAC scores predict worse outcomesclearly identifies those at greater risk and could motivate
greater adherence to preventive therapies; further study is
recommended to determine whether serial CAC measures
can be recommended in certain subgroups to optimize
CHD risk assessment and patient outcomes (32). Also,
radiation exposure has decreased over recent years to below
1 mSv in most cases (10); the CT heart scan is lower in
radiation than most other cardiology diagnostic procedures
and now comparable to mammography (33).
Conclusions
Progression of CAC is associated with incident hard and
total CHD events in a large multiethnic cohort with CAC
scans averaging 2.5 years apart. This suggests that serial
scans may identify some people at high risk of CHD events
who could potentially benefit from a more intense risk factor
modification strategy. Further study should examine if such
a strategy decreases CHD outcomes and is effective and
cost-effective.
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